Lipocine Announces Deletion of Unauthorized Changes to Company's Website
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine's website (www.lipocine.com), without authorization from Lipocine, statements suggesting that TLANDO was approved by the U.S. Food and Drug Administration ("FDA"). TLANDO has not received final approval from the FDA. Upon learning of the unauthorized posting to its website, Lipocine deleted the incorrect posting.
SOURCE Lipocine Inc.
For further information: For further information: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, mb@lipocine.com; Investors - Hans Vitzthum, Phone: (617) 535-7743, hans@lifesciadvisors.com